ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

ClinicalTrials.gov ID: NCT00499252

Public ClinicalTrials.gov record NCT00499252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Evaluation of Abraxane® in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study identification

NCT ID
NCT00499252
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gynecologic Oncology Group
Network
Enrollment
51 participants

Conditions and interventions

Interventions

  • Paclitaxel Albumin-Stabilized Nanoparticle Formulation Drug

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2007
Primary completion
Jun 30, 2011
Completion
Not listed
Last update posted
Jan 10, 2018

Started 2007

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
18
Facility City State ZIP Site status
Colorado Gynecologic Oncology Group Aurora Colorado 80010
The Hospital of Central Connecticut New Britain Connecticut 06050
Beebe Medical Center Lewes Delaware 19958
Rush University Medical Center Chicago Illinois 60612
Union Hospital of Cecil County Elkton Maryland 21921
University of Massachusetts Medical School Worcester Massachusetts 01655
Roswell Park Cancer Institute Buffalo New York 14263
North Shore University Hospital Manhasset New York 11030
North Shore-LIJ Health System CCOP Manhasset New York 11030
University of North Carolina Chapel Hill North Carolina 27599
Wake Forest University Health Sciences Winston-Salem North Carolina 27157
Riverside Methodist Hospital Columbus Ohio 43214
Mount Carmel Health Center West Columbus Ohio 43222
Cancer Care Associates-Midtown Tulsa Oklahoma 74104
Abington Memorial Hospital Abington Pennsylvania 19001
Lehigh Valley Hospital Allentown Pennsylvania 18105
Women and Infants Hospital Providence Rhode Island 02905
University of Texas Medical Branch at Galveston Galveston Texas 77555-0565
Carilion Clinic Gynecological Oncology Roanoke Virginia 24016
University of Washington Medical Center Seattle Washington 98195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00499252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 10, 2018 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00499252 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →